Cell proliferation and carcinogenesis

Journal of Toxicologic Pathology

Volumn 21, Issue 1, 2008, Pages 1-7

  Cohen, Samuel M ^a   Arnold, Lora L ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cell proliferation; Chemical carcinogen; Cytotoxicity; Genotoxicity; Modeling; Risk assessment

Indexed keywords

EID: 42949144553     PISSN: 09149198     EISSN: None     Source Type: Journal    
DOI: 10.1293/tox.21.1     Document Type: Review

References (41)

1. Cohen SM. The role of cell proliferation in the etiology of neoplasia. In: Chemical Carcinogens and Anticarcinogens, Vol. 12 of Comprehensive Toxicology, GT Bowden and SM Fisher (eds). Pergamon (Elsevier), Amsterdam, 401-424. 1997.
2. Hanawalt PC. DNA repair comes of age. Mutat Res. 336: 101-113. 1995.
3. Culotta E and Koshland DE. DNA repair works its way to the top. Science. 266: 1926-1929. 1994.
4. Greenfield RE, Ellwein LB, and Cohen SM. A general probabilistic model of carcinogenesis: Analysis of experimental urinary bladder cancer. Carcinogenesis. 5: 437-445. 1984.
5. Moolgavkar SH and Knudson AG, Jr. Mutation and cancer. A model for human carcinogeneisis. J Natl Cancer Inst. 66: 1037-1052. 1981.
6. Berenblum I and Shubik P. A new quantitative approach to the study of the stages of chemical carcinogenesis in the mouse's skin. Br J Cancer. 1: 384-891. 1947.
7. Weisburger JH and Williams GM. Carcinogen testing: current problems and new approaches. Science. 214: 401-407. 1981.
8. Cohen SM and Ellwein LB. Genetic errors, cell proliferaiion, and carcinogenesis. Cancer Res. 51: 6493-6505. 1991.
9. Cohen SM. Cell proliferation in the evaluation of carcinogenic risk and the inadequacies of the initiation-promotion model. Int J Toxicol. 17: 129-142. 1998.
10. Armitage P and Doll R. The age distribution of cancer and multistage theory of carcinogenesis. Brit J Cancer. 8: 1-12. 1954.
11. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci. 68: 820-823. 1971.
12. Kakizoe T. Development and progression of urothelial carcinoma. Canc Sci. 97: 821-828. 2006.
13. Cohen SM. Cell proliferation and carcinogenesis. Drug Metabolism Rev. 30: 339-357. 1998.
14. Beland FA, Fullerton NF, Kinouchi T, and Poirier MC. DNA adduct formation during continuous feeding of 2-acetylaminoflourene at multiple concentrations. In: Methods for Detecting DNA Damaging Agents in Humans: Application in Cancer Epidemiology and Prevention, H Bartsch, K Heminki, and IK O'Neill (eds). IARC Scientific Publications, IARC, Lyon. Vol 89, 175-180. 1988.
15. Cohen SM and Ellwein LB. Cell proliferation in carcinogenesis. Science. 249: 1007-1011. 1990.
16. 01 study. Toxicol Appl Pharmacol. 104: 79-93. 1990.
17. Preston RJ and Williams GM. DNA-reactive carcinogens: Mode of action and human cancer hazard. Crit Rev Toxicol. 35: 673-684. 2005.
18. Cohen SM, Boobis AR, Meek ME, Preston RJ, and McGregor DB. 4-Aminobiphenyl and DNA reactivity: case study within the context of the 2006 IPCS human relevance framework for analysis of a cancer mode of action for humans. Crit Rev Toxicol. 36: 803-819. 2006.
19. Cairns T. The ED01 study: Introduction, objectives, and experimental design. J Environ Pathol Toxicol. 3: 1-7. 1979.
20. Littlefield NA, Farmer JH, Gaylor DW, and Sheldon WG. Effects of dose and time in a long-term, low-dose carcinogenic study. J Environ Pathol Toxicol. 3: 17-34. 1979.
21. Frith CH, Farmer JH, Greenman DL, and Shaw GW. Biologic and morphologic characteristics of urinary bladder neoplasms induced in BALB/c female mice with 2-acetylaminoflourene. J Environ Pathol Toxicol. 3: 103-119. 1976.
22. Hoseyni MD. Risk assessment for aflatoxin: III. Modeling the relative risk of hepatocullular carcinoma. Risk Analysis. 12: 123-128, 1992.
23. Arai M, St. John M, Fukushima S, Friedell GH, and Cohen SM. Long term dose response study of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide- induced urinary bladder carcinogenesis. Cancer Lett. 18: 261-269. 1983.
24. Hasegawa R, Cohen SM, St. John M, Cano M, and Ellwein LB. Effect of dose on the induction of urothelial proliferation by N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide and its relationship to bladder carcinogenesis in the rat. Carcinogenesis. 7: 633-636. 1986.
25. International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some Chemicals That Cause Tumours of the Kidney or Urinary Bladder in Rodents and Some Other Substances, Vol. 73. 516-624. 1999.
26. Murasaki G and Cohen SM. Co-carcinogenicity of sodium saccharin and N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide for the urinary bladder. Carcinogenesis. 4: 97-99. 1983.
27. Holsapple MP, Pitot HC, Cohen SM, Boobis AR, Klaunig JE, Pastoor T, Dellarco V, and Dragan YP. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci. 89: 51-56. 2006.
28. Lock EA and Hard GC. Chemically induced renal tubule tumors in the laboratory rat and mouse: Review of the NCI/NTP database and categorization of renal carcinogens on mechanistic information. Crit Rev Toxicol. 34: 211-299. 2004
29. Cohen SM. Urinary bladder carcinogenesis. Toxicol Pathol. 26: 121-127. 1998.
30. Cohen SM, Wanibuchi H, and Fukushima S. Lower urinary tract. In: Handbook of Toxicologic Pathology, 2nd ed. WM Haschek, CG Rousseaux, and MA Wallig (eds), Vol. 2. Academic Press, San Diego. 337-361. 2002.
31. Meek ME (Bette), Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-McKeeman LD, Longfellow DG, Pastoor T, Seed J, and Patton DE. Framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol. 33: 591-653. 2003.
32. Boobis AR, Cohen SM, Dellarco V, McGregor D, Meek ME, Vickers C, Willcocks D, and Farland W. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol. 36: 781-792. 2006.
33. Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM, Roberts RA, and Fenner-Crisp PA. PPARα agonist-induced rodent tumors: Modes of action and human relevance. Crit Rev Toxicol. 33: 655-780. 2003.
34. McGregor D, Hermann B, Cogliano V, and Richter-Reichhelm HB. Formaldehyde and glutaraldehyde and nasal cytotoxicity: Case study within the context of the 2006 IPCS human framework for the analysis of a cancer mode of action for humans. Crit Rev Toxicol. 36: 821-835. 2006.
35. Dellarco VL, McGregor D, Berry C, Cohen SM, and Boobis A. Thiazopyr and thyroid disruption: case study within the context of the 2006 IPCS human relevance framework for. analysis of a cancer mode of action. Crit Rev Toxicol. 36: 793-801. 2006.
36. Cohen SM. Human carcinogenic risk evaluation: An alternative approach to the two-year rodent bioassay. Toxicol Sci. 8: 225-229. 2004.
37. Cohen SM. Effects of PPARγ and combined agonists on the urinary tract of rats and other species. Toxicol Sci. 87: 322-327. 2005.
38. Dominick MA, White MR, Sanderson TP, Van Vleet TR, Cohen SM, Arnold LL, Cano M, Tannehill-Gregg S, Moehlenkamp JD, Waites CR, and Schilling BE. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR a√γ vagonist: Evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol. 34: 903-920. 2006.
39. Van Vleet TR, White MR, Sanderson TP, Cohen SM, Cano M, Arnold LL, Waites CR, Schilling BE, Mitroka J, and Dominick MA. Subchronic urinary bladder effects of muraglitazar in male rats. Toxicol Sci. 96: 58-71. 2007.
40. Kawakami S, Arai G, Hayashi T, Fujii Y, Xia G, Kageyama Y, and Kihara K. PPARγ ligands suppress proliferation of human urothelial basal cells in vitro. J Cell Physiol. 191: 310-319. 2002.
41. Varley CL, Stahlschmidt J, Lee W, Holder J, Dibble C, Selby PJ, Trejdosiewicz LK, and Southgate J. Role of PPARγ and EGFR signaling in the urothelial terminal differentiation programme. J Cell Sci. 117: 2029-2036. 2003.